Active substance
Linezolid
- SFDA 15
- US FDA 30
- Health Canada 8
- US price lines 2
- NHS prices 1
- WHO EML 2
- Safety 4
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| DILIZOLEN 600MG TABLET | 600 mg | Tablet · Oral use | 20 Blister | SAR 1404.45 | Generic · Prescription | Glenmark Pharmaceuticals Limited | Valid |
| KINZADO | 600 mg | Film-coated tablet · Oral use | 10 Blister | SAR 1447.20 | Generic · Prescription | SPIMACO ADDWAEIH | Valid |
| LINDEC 600 mg Film-coated Tablet | 600 mg | Film-coated tablet · Oral use | 30 Bottle | SAR 1535.75 | Generic · Prescription | APOTEX INC. (SIGNET SITE) | Valid |
| LINID 2 MG/ML SOLUTION FOR INFUSION | 2 mg/ml | Solution for infusion · Intravenous use | 1 Bag | SAR 144.15 | Generic · Prescription | AJA PHARMACEUTICAL INDUSTRIES | Valid |
| Lenzal | 600 mg | Film-coated tablet · Oral use | 30 Blister | SAR 1877.10 | Generic · Prescription | Alrai Pharmaceutical industry Co. (L.L.C) | Valid |
| Lidolinz | 600 mg | Film-coated tablet · Oral use | 10 Blister | SAR 625.65 | Generic · Prescription | CALIFORNIA GREENS CORPORATION FACTORY | Valid |
| ZERSA 600 mg Film-coated Tablet | 600 mg | Film-coated tablet · Oral use | 10 Blister | SAR 1929.60 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| ZYVOX 2 MG/ML SOLUTION FOR INFUSION | 2 mg/ml | Solution for infusion · Intravenous use | 10 Bag | SAR 1601.75 | NCE · Prescription | PFIZER INC | Valid |
| Zenix | 600 mg | Film-coated tablet · Oral use | 20 Blister | SAR 1137.60 | Generic · Prescription | STADA ARZNEIMITTEL GmbH | Valid |
| Zersa | 20 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 630.00 | NCE · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Zersa | 2 mg/ml | Solution for infusion · Intravenous use | 1 Bag | SAR 136.90 | Generic · Prescription | Jazeera Pharmaceutical Industries (JPI) | Valid |
| Zextro | 600 mg | Film-coated tablet · Oral use | 20 Bottle | SAR 2894.40 | Generic · Prescription | Med City Pharma | Valid |
| Zillion | 600 mg | Film-coated tablet · Oral use | 10 Blister | SAR 1447.20 | Generic · Prescription | Saudi Amarox | Valid |
| Zillion | 20 mg/ml | Oral suspension · Oral use | 1 Bottle | SAR 598.50 | Generic · Prescription | Saudi Amarox | Valid |
| Zodinex | 600 mg | Film-coated tablet · Oral use | 20 Blister | SAR 1251.35 | Generic · Prescription | Middle East Pharmaceutical Industries Co Ltd Avalon Pharma | Valid |
Indications — CHI Daman Drug Formulary
ACUTE EXACERBATION OF BRONCHIECTASIS (NON-CYSTIC FIBROSIS); BACTERIAL MENINGITIS; BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL SKIN INFECTIONS - GAS GANGRENE; BACTERIAL SKIN INFECTIONS - NECROTIZING FASCIITIS; BACTERIAL SKIN INFECTIONS - PURULENT SKIN AND SOFT TISSUE INFECTIONS (CUTANEOUS ABSCESSES, FURUNCLES, CARBUNCLES); BACTERIAL SKIN INFECTIONS - SURGICAL SITE INFECTIONS; COMMUNITY ACQUIRED PNEUMONEA; ENDOCARDITIS; HOSPITAL AND VENTILATER ACQUIRED PNEUMONIA; Pyogenic Arthritis; TRAVEL RELATED INFECTIONS-TREATMENT; TUBERCULOSIS
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| ZYVOX | 200MG/100ML (2MG/ML); 600MG/300ML (2MG/ML) | solution · intravenous | PFIZER | Prescription | 18 Apr 2000 |
| ZYVOX | 100MG/5ML | for suspension · oral | PFIZER | Prescription | 18 Apr 2000 |
| LINEZOLID | 100MG/5ML | for suspension · oral | HIKMA PHARMS | Prescription | 3 Jun 2015 |
| LINEZOLID IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER | 600MG/300ML (2MG/ML) | solution · intravenous | HOSPIRA | Prescription | 18 Jun 2015 |
| LINEZOLID | 200MG/100ML (2MG/ML); 600MG/300ML (2MG/ML) | solution · intravenous | SANDOZ | Prescription | 16 Jul 2015 |
| LINEZOLID | 600MG | tablet · oral | RISING | Prescription | 21 Dec 2015 |
| LINEZOLID | 600MG | tablet · oral | GLENMARK SPECLT | Prescription | 21 Dec 2015 |
| LINEZOLID | 600MG | tablet · oral | HETERO LABS LTD V | Prescription | 21 Dec 2015 |
| LINEZOLID | 600MG | tablet · oral | ALEMBIC | Prescription | 21 Dec 2015 |
| LINEZOLID | 600MG | tablet · oral | ALKEM LABS LTD | Prescription | 21 Dec 2015 |
| LINEZOLID | 600MG/300ML (2MG/ML) | solution · intravenous | FRESENIUS KABI USA | Prescription | 15 Mar 2016 |
| LINEZOLID | 600MG/300ML (2MG/ML) | solution · intravenous | EUGIA PHARMA | Prescription | 4 Aug 2016 |
| LINEZOLID | 600MG | tablet · oral | NOVEL LABS INC | Prescription | 22 Aug 2016 |
| LINEZOLID | 200MG/100ML (2MG/ML); 600MG/300ML (2MG/ML) | solution · intravenous | NANG KUANG PHARM CO | Prescription | 20 Dec 2016 |
| LINEZOLID | 600MG | tablet · oral | ZYDUS PHARMS | Prescription | 22 Feb 2017 |
| LINEZOLID | 200MG/100ML (2MG/ML); 600MG/300ML (2MG/ML) | solution · intravenous | SAGENT PHARMS INC | Prescription | 2 Mar 2017 |
| LINEZOLID | 200MG/100ML (2MG/ML); 600MG/300ML (2MG/ML) | solution · intravenous | HQ SPCLT PHARMA | Prescription | 7 Jul 2017 |
| LINEZOLID | 200MG/100ML (2MG/ML); 600MG/300ML (2MG/ML) | solution · intravenous | STERISCIENCE | Prescription | 6 Dec 2017 |
| LINEZOLID | 600MG | tablet · oral | CHARTWELL RX | Prescription | 25 Apr 2019 |
| LINEZOLID | 600MG/300ML (2MG/ML) | solution · intravenous | HIKMA PHARMS | Prescription | 22 Aug 2022 |
| LINEZOLID | 100MG/5ML | for suspension · oral | HETERO LABS | Prescription | 31 Oct 2022 |
| LINEZOLID | 600MG | tablet · oral | MACLEODS PHARMS | Prescription | 10 Oct 2024 |
| LINEZOLID | 600MG/300ML (2MG/ML) | solution · intravenous | CAPLIN | Prescription | 8 Dec 2025 |
| ZYVOX | 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**; 600MG | tablet · oral | PFIZER | Discontinued | 18 Apr 2000 |
| ZYVOX | 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | solution · intravenous | PFIZER | Discontinued | 18 Apr 2000 |
5 more — full table
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-LINEZOLID | 02426552 | 600 MG | TABLET · ORAL | APOTEX INC |
| JAMP LINEZOLID | 02520354 | 600 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| LINEZOLID INJECTION | 02430827 | 2 MG / ML | SOLUTION · INTRAVENOUS | FRESENIUS KABI CANADA LTD |
| LINEZOLID INJECTION | 02481278 | 2 MG / ML | SOLUTION · INTRAVENOUS | JAMP PHARMA CORPORATION |
| LINEZOLID INJECTION | 02539748 | 2 MG / ML | SOLUTION · INTRAVENOUS | EUGIA PHARMA INC. |
| SANDOZ LINEZOLID | 02422689 | 600 MG | TABLET · ORAL | SANDOZ CANADA INCORPORATED |
| ZYVOXAM | 02243685 | 2 MG / ML | SOLUTION · INTRAVENOUS | PFIZER CANADA ULC |
| ZYVOXAM | 02243686 | 100 MG / 5 ML | POWDER FOR SUSPENSION · ORAL | PFIZER CANADA ULC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | LINEZOLID 100 MG/5 ML SUSP | $2.73583 | per ML | 23 Sep 2026 |
| US NADAC | LINEZOLID 600 MG TABLET | $1.44111 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Linezolid 100mg/5ml oral suspension | £222.50 | 150 ml | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 6.2.3. Reserve group antibiotics · complementary
Methicillin resistant Staphylococcus aureus; Vancomycin resistant Staphylococcus aureus; Vancomycin resistant Enterococcus
Parenteral > General injections > IV: 2 mg per mL in 300 mL bag | Oral > Liquid: 100 mg per 5 mL powder for oral liquid | Oral > Solid > dispersible tablet: 150 mg (EMLc) | Oral > Solid > tablet: 600 mg (EML) - 6.2.5. Antituberculosis medicines · core
Multi-drug resistant Mycobacterium tuberculosis
Oral > Solid > dispersible tablet: 150 mg (scored) (EMLc) | Oral > Solid > tablet: 600 mg
Safety signals and safety-related labeling changes
- US FDA 9 Jun 2026 ZYVOX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Jun 2026 ZYVOX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - US FDA 9 Jun 2026 ZYVOX — safety-related labeling change
Labeling sections changed: Warnings and Precautions; Adverse Reactions; Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide - MHRA 11 Dec 2014 Linezolid: restricted indication
Linezolid is not active against infections caused by Gram-negative pathogens, and treatment should be started only after specialist microbiological advice.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.